Management of Multiple Myeloma: Using Emerging Therapies with ASCT
Multiple myeloma (MM) management has undergone profound changes in the past few decades, this is largely due to advances in understanding the disease biology and the development of new therapeutic options. However, this progress has also led to an increasingly complex treatment environment. Numerous questions remain, particularly in the transplant setting, such as the role of high-dose chemotherapy, the use of continuous/maintenance therapy, and the best treatment sequence for a patient with multiple myeloma.
In this CME activity, leading experts in multiple myeloma will review changes in the treatment paradigm, optimal patient selection for transplant, and data from recent clinical trials. They will also provide insight into new strategies for individualized management, the role of early versus late transplant, and how to incorporate novel therapies into clinical practice.
Accreditation Statement for Joint Provider Activities:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin, Vindico Medical Education, and Carden Jennings Publishing. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Spectrum Pharmaceuticals, Inc.; and Takeda Oncology.
Click here to access Bloodline.
The intended audience for this activity is hematologists, oncologists, bone marrow transplant specialists, and other health care professionals who provide care for patients with multiple myeloma (MM).
Upon successful completion of this educational activity, participants should be better able to:
- Review the eligibility criteria for stem cell transplant in patients with MM in both the frontline and relapse/refractory settings.
- Apply clinical evidence for optimal induction, conditioning, and consolidation strategies in patients with MM undergoing stem cell transplant.
- Utilize effective maintenance therapy in patients with MM who have completed stem cell transplant.
Kenneth C. Anderson, MD
Kraft Family Professor of Medicine, Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Joseph R. Mikhael, MD, MEd, FRCPC, FACP
Professor of Medicine, Mayo College of Medicine
Associate Dean, Mayo School of Graduate Medical Education
Deputy Director - Education, Mayo Clinic Cancer Center
Associate Medical Director, Department of Development
Mayo Clinic in Arizona
In accordance with the ACCME® standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved:
Kenneth C. Anderson, MD, discloses that he has been on the Advisory Board for Celgene, Gilead, and Millennium. He also is a Scientific Founder for Acetylon, C4 Therapeutics, and OncoPep.
Joseph R. Mikhael, MD, MEd, FRCPC, FACP, discloses that he has received Institutional Research Funding (Clinical Trials) for AbbVie, Celgene, Onyx, and Sanofi.
Valerie Zimmerman, PhD, medical writer, has no relevant financial relationships to disclose.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.